Abstract Type : Poster  
Presentation No. : PTL 006

**Development of De Novo Anti-HLA Antibodies in Kidney Transplant Recipients**

**Ho Sik Shin**¹, Guleria I², Ikle D³, Vincenti F⁴, Morrison Y⁵, Nickerson P⁶, Bridges N⁷, Harmon W⁷, Sayegh MH²

¹Department of Internal Medicine-Nephrology, Kosin University Gospel Hospital, Korea, Republic of Korea  
²Department of Internal Medicine-Nephrology, Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, United States  
³Department of Internal Medicine-Nephrology, Rho, Chapel Hill, United States  
⁴Department of Internal Medicine-Nephrology, Connie Frank Transplant Center, UCSF, United States  
⁵Department of Internal Medicine-Nephrology, Transplantation Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States  
⁶Department of Internal Medicine-Nephrology, Boston Children’s Hospital and Harvard Medical School, United States  
⁷Department of Departments of Medicine and Immunology, University of Manitoba, United States

**Objectives:** The risk factors associated with the development of post-transplant *de novo* anti-HLA antibodies in unsensitized kidney transplant recipients remain inadequately characterized. The Clinical Trials in Organ Transplantation CTOT-02/CCTPT-02 study was a prospective multicenter clinical trial designed to identify subjects who developed *de novo* anti-HLA antibodies following kidney transplantation.

**Methods:**

Unsensitized subjects were enrolled after kidney transplantation and monitored at 3-month intervals for antibody development for at least two years and as long as 5 years.

**Results:** Among 653 subjects from 18 centers ranging in age from 3 to 70 (median age, 45) years, 79 subjects (12%) developed at least one *de novo* anti-HLA antibody. Multivariate analysis indicated that pediatric subjects were significantly more likely to develop anti-HLA antibodies compared with subjects >18 years old. On the other hand, use of anti-IL-2R antibody induction therapy was protective against anti-HLA antibody development. The presence of *in vitro* complement (C1q) binding antibody was associated with rejection (OR=4.80 (1.39-16.59), *p*=0.013).

**Conclusions:**

In a low risk kidney transplant population, the risk of developing anti-HLA antibodies was greater in children <18 years of age compared with adults, and greatest in young children (<12 years). Induction with an anti-IL-2R antibody was protective against the development of anti-HLA antibodies regardless of age.